Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
| Autor: | Younjeong Choi, Bong Soo Cha, Yong Ho Lee, Chul Woo Ahn, Jiwon Seo, Hye Jin Wang, Yujung Yun, Eun Seok Kang, EunYeong Choe, Yongin Cho, Hyun Chul Lee |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Simvastatin Statin medicine.drug_class Endocrinology Diabetes and Metabolism Atorvastatin Hypercholesterolemia Endocrinology Risk Factors Internal medicine Diabetes mellitus medicine Diabetes Mellitus Humans Rosuvastatin Pyrroles cardiovascular diseases Rosuvastatin Calcium Pitavastatin Aged Pravastatin Retrospective Studies Sulfonamides biology business.industry nutritional and metabolic diseases Middle Aged Impaired fasting glucose medicine.disease Fluorobenzenes Pyrimidines Heptanoic Acids HMG-CoA reductase biology.protein Quinolines lipids (amino acids peptides and proteins) Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Metabolism: clinical and experimental. 64(4) |
| ISSN: | 1532-8600 |
| Popis: | Objective 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are used to control blood cholesterol levels and reduce cardiovascular disease. It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM). However, limited evidence exists from direct head to head comparisons of statins on whether the risk of DM differs among statins. We investigated the risk of development of new-onset diabetes in subjects treated with different statins. Methods We retrospectively enrolled consecutive 3680 patients without DM or impaired fasting glucose who started receiving statin treatment for cholesterol control. We evaluated the incidence of new-onset diabetes according to the type of statin. Results The mean duration of follow-up was 62.6 ± 15.3 months. The incidence of DM was significantly higher in the pitavastatin group (49 of 628; 7.8%) compared to that in the other statin groups [atorvastatin (68 of 1327; 5.1%), rosuvastatin (77 of 1191; 6.5%), simvastatin (11 of 326; 3.4%), and pravastatin (12 of 298; 5.8%); p = 0.041]. The risk of diabetes was the highest in the pitavastatin group compared with that in the simvastatin group [hazard ratio (HR) = 2.68, p = 0.011]. Other statins showed no significant risk differences compared to that for simvastatin. Fasting blood glucose (FBG) level at baseline and body-mass index (BMI) were associated with the development of diabetes [FBG, HR = 1.11, p Conclusions Among the five statins, pitavastatin showed the strongest effect on the development of new-onset diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect